Post-treatment late complications of nasopharyngeal carcinoma

被引:44
作者
Lee, Cheng-Chang [1 ,2 ]
Ho, Ching-Yin [1 ,2 ]
机构
[1] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Otolaryngol, Taipei 11217, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei 11217, Taiwan
关键词
Nasopharyngeal carcinoma; Late complications; Quality of life; Radiotherapy; Chemoradiation; Intensity-modulated radiotherapy; INTENSITY-MODULATED RADIOTHERAPY; QUALITY-OF-LIFE; RADIATION-THERAPY; CONCURRENT-CHEMOTHERAPY; CANCER; TRIAL;
D O I
10.1007/s00405-011-1922-2
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Radiotherapy (RT) or concurrent chemoradiation therapy (CCRT) is not only effective at patients' survival rates, but also produces undesirable late complications. The purpose of this study is to investigate the post-treatment late complications in nasopharyngeal carcinoma (NPC) patients, and to analyze the individual impact factors. We enrolled 188 newly diagnosed NPC patients who had received complete treatments and at least 3 years' follow-up between March 1984 and March 2010. Late complications were modified from the Toxicity Criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer. Of 188 patients, 132 were male and 56 were female. Eighty-eight patients received CCRT and the other 100 patients received RT alone. The median follow-up duration was 7.34 years (range 3.30-26.54). Only 5.3% of patients reported no complication during post-treatment follow-up. The most common major and minor complications were osteoradionecrosis (10.1%) and xerostomia (56.4%), respectively. There was no impact factor for age, underlying disease, and cancer staging. However, there was a negative impact factor for xerostomia and limb numbness in the CCRT group compared with the RT group. Besides, re-radiation for recurrent patients could increase the risk of major complications. Fortunately, these major complications were reduced after the introduction of intensity-modulated radiotherapy in 2003. The improvement of treatment modality decreased the risk of major complications. Physicians should pay more attentions and improve patients' quality of life during follow-up.
引用
收藏
页码:2401 / 2409
页数:9
相关论文
共 27 条
[1]   Nasopharyngeal carcinoma: Clinical assessment and review of 176 cases [J].
August, M ;
Dodson, TB ;
Nastri, A ;
Chuang, SK .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 2001, 91 (02) :205-214
[2]  
Bureau of Health Promotion, 2008, CANC REG ANN REP 200, P28
[3]   Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx [J].
Cooper, JS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (05) :1277-1279
[4]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[5]   Quality of life and oral function in patients treated with radiation therapy for head and neck cancer [J].
Epstein, JB ;
Robertson, M ;
Emerton, S ;
Phillips, N ;
Stevenson-Moore, P .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (05) :389-398
[6]   PERIPHERAL NEUROPATHY AND LOW-DOSE CISPLATIN [J].
GREENSPAN, A ;
TREAT, J .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (06) :660-662
[7]   Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors [J].
Hao, Sheng-Po ;
Tsang, Ngan-Ming ;
Chang, Kai-Ping ;
Hsu, Yung-Shin ;
Chen, Chin-Kuo ;
Fang, Ku-Hao .
ACTA OTO-LARYNGOLOGICA, 2008, 128 (04) :473-481
[8]   Diagnosis and management of skull base osteoradionecrosis after radiotherapy for nasopharyngeal carcinoma [J].
Huang, Xiao-Ming ;
Zheng, Yi-Qing ;
Zhang, Xiang-Min ;
Mai, Hai-Qiang ;
Zeng, Liang ;
Liu, Xiang ;
Liu, Wei ;
Zou, Hua ;
Xu, Geng .
LARYNGOSCOPE, 2006, 116 (09) :1626-1631
[9]  
Hughes PJ, 2000, HEAD NECK-J SCI SPEC, V22, P393, DOI 10.1002/1097-0347(200007)22:4<393::AID-HED13>3.0.CO
[10]  
2-2